Posted by Michael Wonder on 16 Jul 2024
Arrivo announces FDA fast track designation for RABI-767 for patients with acute pancreatitis predicted to progress to severe disease
15 July 2024 - RABI-767 is a novel lipase inhibitor currently in a Phase 2a clinical trial.
Arrivo BioVentures announced today that the US FDA granted its subsidiary, Panafina, fast track designation for its investigational new drug, RABI-767, for the treatment of patients with acute pancreatitis predicted to progress to severe disease.
